Фармакоэпидемиологические и фармакогенетические подходы к оптимизации антикоагулянтной терапии у пациентов с фибрилляцией предсердий
Диссертация
Однако, несмотря на многолетний опыт использования варфарина, подбор его дозы до сих пор представляет существенную проблему в связи с такими особенностями OAK, как узкий терапевтический диапазон, вариабельная фармакокинетика и фармакодинамика, многочисленные лекарственные взаимодействия, создающие угрозу развития избыточной гипокоагуляции и серьезных кровотечений. Именно этот факт вероятнее всего… Читать ещё >
Список литературы
- Авксентьева М.В., Воробьев П. А. Учет и оценка затрат // Клинико-экономический анализ / Под ред. П. А. Воробьева. М.: Ньюдиамед, 2004. -С. 176−201.
- Алексеевская И.Н., Персидских Ю. А., Корнелюк И. В. с соавт. Факторы, ассоциированные с возникновением тромбоза ушка левого предсердия у пациентов с персистирующей фибрилляцией предсердий // Вестник аритмологии. 2009. — № 56. — С. 20 — 24.
- Аркадьева Г. В., Радзевич А. Э., Козлова Т.В.и др. Лечение оральными антикоагулянтами: Метод, рекомендации. М.: Изд-во ГОУ ВПО МГМСУ Росздрава, ГОУ ВПО ММА им. И. М. Сеченова, 2009. — 48 с.
- Байдак Д.В. Влияние полиморфизма гена, кодирующего витамин К эпоксид редуктазу (VKORC1) на эффективность и безопасность непрямых антикоагулянтов варфарина и аценокумарола: Автореф. дисс.. канд. мед. наук. — М., 2007. — 24 с.
- Зеленин В.Ф. Болезни сердечно-сосудистой системы. М.: Медгиз, 1956. -331 с.
- Инструкция по медицинскому применению препарата Варфарин Нико-мед // Доступно на сайте: http://medi.ru/doc/a7956.htin.
- Карпов P.C. Аритмии и блокады сердца // Внутренние болезни / Под ред. А. И. Мартынова, H.A. Мухина, B.C. Моисеева. В 2-т. М.: ГЭОТАР-Медиа, 2002.-Т. I. -600 с.
- Концепция развития здравоохранения Российской Федерации до 2020 года. // Доступно на сайте: http://www.minzdravsoc.ru/map.
- Корпачева Е. Эволюция системы стратификации риска тромбоэмболиче-ских осложнений у больных мерцательной аритмией // Русский медицинский журнал. 2010. — № 22. — С. 1307−1311.
- Кукес В.Г. Клиническая фармакология. М.: ГЭОТАР-МЕД, 2006. — 938 с.
- Лаборатория НИИ антимикробной химиотерапии. Виды и стоимость исследований (метод полимеразной цепной реакции в режиме реального времени) // Доступно на caйтe: http://www.infections.ru/laboratories/pcr/ price-pcr.html
- Лоуренс Д.Р., Бенитт П. Н. Клиническая фармакология. В 2 т. М.: Медицина, 1991. Т. I. — 656 с.
- Мешков А.П. Электрокардиография. Горький: Горьковский медицинский институт им. С. М. Кирова, 1983. -104 с.
- Нестерова О., Рычков А., Хорькова Н. и др. Риск тромбоэмболических осложнений и адекватность применения варфарина при фибрилляции предсердий неклапанной этиологии // Вестник аритмологии. 2010. — № 62.-С. 41−44.
- Орлов В.Н. Руководство по электрокардиографии. М.: ООО «Медицинское информационное агентство», 2001. — 528 с.
- Основы клинической фармакологии и рациональной фармакотерапии / Под ред. Ю. Б. Белоусова, М. В. Леоновой. М.: Бионика, 2002. — 368 с.
- Панченко Е.П. Профилактика кардиоэмболического инсульта у больных мерцательной аритмией // Кардиоваскулярная терапия и профилактика. -2003.-№ 3,-С. 64−69.
- Парфенов В., Хатькова С., Воронцов М. Факторы риска, течение и вторичная профилактика при патогенетических подтипах ишемических инсультов // Неврологический журнал. 2010. — № 6. — С. 16−20.
- Приказ № 397 Минздрава РФ «Об организации работ по внедрению Федерального Руководства для врачей по использованию лекарственных средств"от 10.11.2000 г.//Доступно на сайте: http://www.rspor.ru/mods/normdoc/mz3972000.pdf
- Сироткина О., Вавилова Т. Фармакогенетике антитромботических препаратов // Тромбоз, гемостаз и реология. 2007. — № 2. — С. 3−9.
- Сироткина О.В., Улитина A.C., Тараскина А. Е. и соавт. Клиническое значение аллельных вариантов гена цитохрома CYP2C9 при антикоагулянт-ной терапии варфарином // Кардиология. 2005. — Т. 45, № 4. — С. 61−63.
- Средняя зарплата в Смоленской области выросла за год на 13 процентов // Доступно на сайте: http://www.smolnews.ru/news/63 766.
- Сычев Д.А., Раменская Г. В., Игнатьев И. В., Кукес В. Г. Клиническая фар-макогенетика. М.:ГЭОТАР-Медиа, 2007. — 50 с.
- Улитина А.С. Молекулярный анализ генов цитохрома Р450 2С9 и витамин К-эпоксид редуктазы VKORC1 в лабораторном контроле терапии варфарином: Автореф. дисс.. канд. мед. наук СПб., 2006. — 16 с.
- Фармакоэкономика и фармакоэпидемиология практика приемлемых решений / Под ред. В. Б. Герасимова, А. Л. Хохлова, О. И. Карпова. — М.: Медицина, 2005. — 352 с.
- Фогельсон Л.И. Нарушения ритма сердца: Руководство по внутренним болезням / Под ред. А. Л. Мясникова. В 2-т. М.:Медгиз, 1962. Т. I. — С. 143 -242.
- Чазов Е.И. Смертность от сердечно-сосудистых заболеваний // Доступно на сайте: http: / /то smedc 1 i ni с. ru/ne ws/160.
- Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillations: Stroke Prevention in Atrial Fibrillation III randomized clinical trial // Lancet. 1996. — Vol. 348. — P. 633−638.
- Agarwal S., Bennett D., Smith D. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting // Am J Cardiovasc Drugs. 2010. — Vol. 10(1) .-P. 37−48.
- Agmon Y., Khandheria B.K., Gentile F., Seward J.B. Echocardiographic assessment of the left atrial appendage // J Am Coll Cardiol. 1999. — Vol. 34. -P. 1867−1877.
- Aithal G.P., Day C.P., Kesteven P. J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications//Lancet. 1999.-Vol. 353.-P. 717−719.
- Anderson J.L., Home B.D., Stevens S.M., et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulant // Circulation. 2007. — Vol. 116. — P. 2563−2570.
- Ansell J., Hirsh J., Hylek E., et al. The Pharmacology and Management of the Vitamin К Antagonists. American College of Chest Physicians Evidence
- Based Clinical Practice Guidelines (8th Edition) // Chest. 2008. — Vol. 133. -P. 160−198.
- Asalcura H., Hifumi S., Jokaji H., et al. Prothrombin fragment Fl+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation // Blood Coagul Fibrinolysis. 1992. — Vol. 3. — P. 469−473.
- Asinger R.W., Koehler J., Pearce L.A., et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation, II: dense spontaneous echo-cardiographic contrast (SPAF-III study) // J Am Soc Echocardiogr. 2000. -Vol. 12.-P. 1080−1087.
- Bar-Sela S., Ehrenfeld M., Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation//Arch Intern Med. 1981.-Vol. 141.-P. 1191−1192.
- Becquemont L. Evidence for pharmacogenetic adapted dose of oral anticoagulant in routine medical practice // Eur J Clin Pharmacol. 2008. — Vol. 64 (10) .-P. 953−960.
- Begley C.E., Famulari M., Annegers J.F., et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data // Epilepsia. 2000. — Vol. 41. — P. 342−351.
- Benjamin E. J, Wolf P.A., D’Agnostico R.B., et al. Impact of atrial fibrillation on the risk of death: the Framingam Heart study // Circulation. 1998. — Vol. 98.-P. 946−952.
- Benjamin E.J., Levy D., Vaziri S.M., D’Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in population-based cohort: the Framingham Heart Study // JAMA. 1994. — Vol. 271. — P. 840−844.
- Beyth R.J., Quinn L., Landefeld C.S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized controlled trial // Ann Intern Med. 2000. — Vol. 133. — P. 687−695.
- Bogousslavsky J, Van Melle G, Regly F., Kappenberg L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry//Neurology. 1990. — Vol. 40. — P. 1046−1050.
- Bogousslavsky J., Cachin C., Regli F., et al. Cardiac sources of embolism and cerebral infarction clinical consequences and vascular concomitants: the Lausanne Stroke Registry//Neurology. — 1991. — Vol. 21. — P. 855−859.
- Bombardier C. Research challenges- overview of epidemiological study design. // J Reumatol. 1998. — Vol. 15 (Suppl. 17). — P. 5−8.
- Boysen G., Nyboe J., Appleyard M. Et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark // Stroke. 1988. — Vol. 19. — P. 1345−1353.
- Brodie D.C. Drug utilization review: planning. Hospitals 1972- 46: P. F03−12.
- Brophy M., Snyder K., Gaehde S., et al. Anticoagulant use for atrial fibrillation in the elderly // J Am Geriatr Soc. 2004. — Vol. 52. — P. 1151−1156.
- Cairns J.A., Connolly S.J. Nonrheumatic atrial fibrillation: risk of stroke and role of antithrombotic therapy // Circulation. 1991. — Vol. 84. — P. 469−481.
- Chiquette E., Amato Mg., Bussey H.I. Comparison of an anticoagulation clinical and usual medical care: anticoagulation control, patients outcomes, and health care costs//Arch Intern Med. 1998. — Vol. 158.-P. 1641−1647.
- Choonara I.A., Malia R.G., Haynes B.P., et al. The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin // Br J Clin Pharmacol. 1988. — Vol. 25. — P. 1−7.
- Choudhry N.K., Anderson G.M., Laupacis A., et. al Impact of adverse events on prescribing warfarin in patients with atrial fibrillation- matched pair analysis // BMJ. 2006. — Vol. 332. — P. 141−145.
- Choudhry N.K., Soumerai S.B., Normand S.L., et. al Warfarin prescribing in atrial fibrillation: the impact of physician, patient and hospital characteristics // Am J Med. 2006. — Vol. 199(7). — P. 607−615.
- Cohen N., Almoznino-Sarafian D., Alon I., et. al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission // Stroke. 2000. -Vol. 31.-P. 1217−1222.
- Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. // N Engl J Med. -2011. Vol.364(9). — P. 806−817.
- Connolly S .J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation // N Engl J Med. 2009. — Vol. 361. — P. 11 391 151.
- Conolly S.J., Laupacis A., Gent M., et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study // J Am Coll Cardiol. 1991. — Vol. 18. — P. 349 355.
- Cooper G.M., Johnson J.A., Langaee T.Y., et al. A genom-wide scan for common genetic variants with a large influence on warfarin maintenance dose // Blood. 2008. — Vol. 112. — P. 1022−1027.
- Critical Path Initiative: warfarin dosing. US Food and Drug Administration. On the Internet: http://www.fda.gov./oc/initiatives/criticalpath/warfarin.html. Accessed 5 Sep 2007.
- Cushman M., Booth S.L., Possidente C.J. et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment // Br J Haematol. -2001,-Vol. 112.-P. 572−577.
- D’Andrea G., D’Ambrosio R., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin // Blood. 2005. — Vol. 105(2). — P. 645−649.
- Dittrich H.C., Pearce L.A., Asinger R.W. et al., for the Stroke Prevention in Atrial Fibrillation Investigators. Left atrial diameter in nonvalvular atrial fibrillation: an Echocardiographic study // Am Heart J. 1999. — Vol. 137. — P. 494 499.
- Drug information for the Health Care Professional. USP DI. 23rd edition. 6200 S. 2003.
- EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke // Lancet. 1993. — Vol. 342. — P. 1255−1262.
- Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials // Arch Intern Med. -1998.-Vol. 158.-P. 1316- 1320.
- Eckman M., Rosand J., Greenberg S., et al. Cost-effectiveness of using phar-macogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation // Ann Intern Med. 2009. — Vol. 150. — P. 73−83.
- Einarson T.R., Bergman U., Wiholm B.E. Principles and practice of pharmacoepidemiology. In: Speight T.M., Holford N.H.G., editors. Avery’s Drug Treatment. 4th ed. New Zealand: Adis International Limited- 1997. p.371−392.
- Elliott R., Woodward M., Oborone C. Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing // Age Ageing. 2002. — Vol. 31(5). — P. 327−328.
- European Atrial Fibrillation Trail Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia // N Engl J Med. 1995. — Vol. 333. — P. 5−10.
- Evans W., Swann P. Lone auricular fibrillation // Br Heart J. 1954. Vol. 16. -P. 189−194.
- Fang M.C., Stafford R.S., Ruskin J.N., et al. National trends of antiarrhythmic and antithrombotic medication use in atrial fibrillation // Arch Intern Med. -2004,-Vol. 164.-P. 55−60.
- Fatlcin D., Kelly R.P., Feneley M.P. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo // J Am Coll Cardiol. 1994. — Vol. 23. — P. 961−969.
- FDA approves updated warfarin (Coumadin) prescribing information. 16 Aug 2007. US Food and Drug Administration. On the Internet: http://www.fda.gov./bbs/topics/NEWS/2007/NEW01684.html. Accessed 4 Sep 2007.
- Feinberg W.M., Seeger J.F., Carmody R., et al. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation // Arch Intern Med. 1990. — Vol. 150. — P. 2340−2344.
- Foster E.J., Velasco J.M., Hieken T.J. Adverse outcomes associated with noncompliance with melanoma treatment guidelines // Ann Surg Oncol. 2008. -Vol. 15(9).-P. 2395−2402.
- Friberg L., Hammar N., Rosenquist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur Heart J. 2010. -Vol. 31.-P. 967−975.
- Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) // Am J Cardiol. 1994.-Vol. 74. — P. 236−241.
- Fuster V. et al. ACC/AHA/ESC 2006 Guidelines for the Management of patients with Atrial Fibrillation // JACC. 2006. — V. 48 (4). — P. 854−906.
- Gage B., Eby C., Johnson J., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin // Clin Pharmacol Ther. 2008. -Vol. 84(3) .-P. 326−331.
- Gage B.F. Can we rely on RE-LY?//N Engl J Med 2009. Vol. 361:1200−02.
- Gage B.F., van Walraven C., Pearce R., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin // Circulation. 2004. — Vol. 110(16). — P. 2287−2292.
- Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation // JAMA. 2001. — Vol. 285. — P. 2864−2870.
- Gage B.F., Yan Y., Milligan P.E., et. Al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)//Am Heart J. 2006. — Vol. 151(3).-P. 713−719.
- Geisen C., Watzka M., Sittinger K., et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation // Thrombosis and Haemostasis. 2005. — Vol. 94. — P. 773−779.
- Glazer N., Dublin S., Smith N., et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines // Arch Intern Med. 2007. — Vol. 167(3) .-P. 246−252.
- Goeree R., O’Brien B.J., Blackhouse G., et al. The valuation of Productivity Costs Due to Premature Mortality: a Comparison of the Human-Capital and Friction-Cost Methods for Schizophrenia // Canadian Journal of Psychiatry. -1999.-Vol. 44.-P. 455−463.
- Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // European Heart Journal. 2010. — Vol. 31. — P. 2369−2429.
- Gullov A.L., Koefoed B.G., Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASK 2 study. Atrial Fibrillation Aspirin and Anticoagulation // Arch Intern Med. 1999. — Vol. 159. — P. 1322−1328.
- Hart R.G. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation (Letter) // Ann Intern Med. 1998. — Vol. 128. — P. 408.
- Hart R.G., Benavente O., McBride R., et al. Antithrombotic therapy to prevent stroke in patient with atrial fibrillation: a meta-analysis // Ann Intern Med. -1999.-Vol. 131.-P. 492−501.
- Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention // Ann Intern Med. 1999. — Vol. 131. — P. 688 695.
- Hart R.G., Pearce L.A., Rothbart R.M., et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in
- Atrial Fibrillation Investigators // J Am Coll Cardiol. 2000. — Vol. 35. — P. 183−187.
- Hartzema A.G. Pharmacoepidemiology its relevance to clinical practice // J Clin Pharm and Therapeutics. — 1992. — Vol. 17. — P. 73−74.
- Heerdink E. R, Urquhart J, Leufkens HG. Changes in prescribed Drug doses after market introduction // Pharmacoepidemiol Drug Saf. 2002. — Vol. 11.-P. 447−453.
- Heeringa J., van der Kuip D., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study // Eur Heart J. 2006. -Vol. 27.-P. 949−953.
- Heneghan C., Alonso-Coello P., Garcia-Alamino J.M., et al. Self-monitoring of oral anticoagulation: a systemic review and meta-analysis // Lancet. 2006. -Vol. 367.-P. 404−411.
- Heppell R.M., Berkin K.E., Mc Lenachan J.M., Davies J.A. Haemostatic and haemodinamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation // Heart. 1997. — Vol. 77. — P. 407−411.
- Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy // JAMA. 2002. — Vol. 287. — P. 1690−1698.
- Hillman M.A., Wilke R.A., Yake S.H., et al. A prospective, randomized pilot trail of model-based warfarin dose initiation using CYP2C9 genotype and clinical data // Clin Med Res. 2005. — Vol. 3. — P. 137−145.
- Hirsh J., Dalen J.E., Poller L., et al. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range // Chest. 1998. — Vol. 114.-P. 445−469.
- Hirth R.A., Chernew M.E., Miller E., et al. Willingness to Pay for a Quality-Adjusted Life Year: in Search of a Standard // Medical Decision Making. -2000.-Vol. 20.-P. 332−342.
- Holbrook A.M., Pereria J. A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions // Arch Intern Med. 2005. — Vol. 165. — P. 1095−1106.
- Hughes M., Lip G.Y. Stroke and thrombormbolism in atrial fibrillations systematic review of stroke risk factors, risk stratification schema and cost effectiveness data // Thromb Haemost. 2008. — Vol. 99. — P. 295−304.
- Hurley D.M., Hunter A.N., Hewett M.J., Stocking J.R. Atrial fibrillation and arterial embolism in hyperthyroidism // Aust N Z Med. 1981. — Vol. 11. — P. 391−393.
- Hwang J.J., Ко F.N., Li Y.H. Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation // Cardiology. 1994. — Vol. 85. — P. 69−75.
- Hylelc E.M., Go A.S., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality of atrial fibrillation // N Engl J Med. 2003. -Vol. 349.-P. 1019−1026.
- Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin // Ann Intern Med. 1994. — Vol. 120. — P. 897−902.
- Important Variant Information for VKORC: портал Электронный ресурс. -Режим доступа: http://www.pharmgkb.org/search/annotatedGene/vkorcl/variant.isp. Дата обращения: 18.11.2008 г.
- Joffe H.V., Xu R., Johnsos F.B., et al. Warfarin dosing and cytochrome P450 CYP2C9 polymorphisms // Thromb Haemost. 2004. — Vol. 91. — P. 11 231 128.
- Kangelaris K., Bent S., Nussbaum R., et al. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin // J Gen Intern Med. 2009. — Vol. 24(5). — P. 656−64.
- Kempster P.A., Gerraty R.P., Gates P.C. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation // Stroke. 1988. — Vol. 19. — P. 955 957.
- Kennedy D. Assessing national drug utilization in the United States. WHO Drug Utilization Research Group Meeting. 1983 Aug 5- Washington, USA.
- Khan T., Wynne H., Wood P., et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin // Br J Haematol. -2004. Vol. 124. — P. 348−354.
- Koopmanschap M.A., Rutten F.F.H., van Ineveld B.M., et al. The Friction Cost Method for Measuring Indirect Costs of Disease // Journal of Health Economics. 1995. — Vol. 14. — P. 171−189.
- Kopecky S.L., Gersh B.J., McGoon M.D. et al. The natural history of lone atrial fibrillation: a population-based study over three decades // N Engl J Med. -1987.-Vol. 317.-P. 669−674.
- Lackner T.E. Pharmacogenomic dosing of warfarin: ready or not? // Consult Pharm. 2008. — Vol. 23(8). — P. 614−619.
- Landefeld C.S., Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy // Am J Med. 1989. — Vol. 87. — P. 144−152.
- Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 CYP2C9 polymorphisms: a comprehensive review of the in-vitro and human data // Pharmacogenetics. 2002. — Vol. 12. — P. 251−263.
- Lee J.A.H., Draper P.A., Weatherall M. Prescribing in three English towns // Milbank Mem Fund Q. 1965. — Vol. 43. — P. 285−290.
- Leey J., McCabe S., Koch J., et al. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation // Am J Geriatr Pharmacother. 2009. — Vol. 7(4). — P. 197−203.
- Levine N.M., Schulman S., Beyth R., et al. Hemorrhagic Complications of anticoagulant Treatment. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. 2008. — Vol. 133. — P. 257−298.
- Li T., Chang C.Y., Jin D.Y., et al. Identification of the gene for vitamin K epoxide reductase // Nature. 2004. — Vol. 427. — P. 493−494.
- Li T., Lange L.A., at al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patient receiving anticoagulation // J Med Genet. 2006. — Vol. 43. — P. 740−749.
- Lin H.J., Wolf P.A., Kelly-Hayes M., et al. Stroke severity in atrial fibrillation: the Framingham Study // Stroke. 1996. — Vol. 27. — P. 1760−1764.
- Lin L., Cheng M., Lee C., et al. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation a nationwide descriptive study in Taiwan // Clin Pharm. — 2008. — Vol. 30(9). — P. 1726−1736.
- Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meat-analysis // Ann Intern Med. 2003. — Vol. 139 (11). — P. 839−900.
- Lip G.Y. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation (comment) // Heart. 1997. — Vol. 77. — P. 395−396.
- Lip G.Y., Lowe G.D., Rumley A., et al. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis // Am Heart J. 1996. — Vol. 131. — P. 724−730.
- Lloyd-Jones D.M., Wang T.J., Leip E.P. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study // Circulation. 2004. — Vol. 110. -P. 1042−1046.
- Mahmud A., Bennett K., Okechukwu I, et al. National underuse of antithrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing // Br J Clin Pharmacol. 2007. — Vol. 64(5). — P. 706−709.
- Majeed A., Moser K., Caroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994−1998: analysis of data from the general practice research database // Heart. 2001. — Vol. 86.-P. 284−288.
- Manotti C., Moia M., Palareti G., et al. Effect of computer aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT // Haematologica. 2001. — Vol. 86. — P. 1060−1070.
- Manucci P.M. Genetic control of anticoagulation. Lancet. 1999. — Vol. 353. -P. 688−689.
- Margaglione M., Colazzo D., D’Andrea G., et al. Genetic modulation of oral anticoagulation with warfarin// Thromb Haemost. 2000. — Vol. 84. — P. 775 778.
- Meade T.W. Prescribing of chloramphenicol in general practice // BMJ. -1967. Vol. 1 (5541). — P. 671−674.
- Meckley L.M., Wittkowsky A.K., Rieder M.J., et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation relates outcomes in warfarin-treated patients // Thromb Haemost. 2008. — Vol. 100. — P. 229 239.
- Menendez R., Ferrando D., Valles J.M., et al. Influence of deviation from guidelines on the outcome of community-acquired pneumonia // Chest. 2002. -Vol. 122(2).-P. 612−617.
- Micieli G., Cavallini A., Quaglini S., et al. Guideline compliance improves stroke outcome: a preliminary study in 4 districts in the Italian region of Lom-bardia // Stroke. 2002. — Vol. 33(5). — P. 1341−1347.
- Miller V.T., Rothrock J.F., Pearce L.A., et al. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators // Neurology. 1993. — Vol. 43. — P. 32−36.
- Mitush R., Lange V., Stierle U., Maurer B., et al. Transesophageal echocardio-graphic determinants of embolism in nonrheumatic atrial fibrillation // Int J Card Imaging. 1995. — Vol. 11. — P. 27−34.
- Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmest County, Minnesota, 1980 to 2000, and implicationson the projections for future prevalence // Circulation. 2006. — Vol. 114. — P. 119−125.
- Naccarelli G.V., Varker H., Lin J., et al. Increasing prevalence of atrial fibrillation and flutter in United States// Am J Cardiol. 2009. — Vol. 104. — P. 15 341 539.
- Nelsestuen G.L., Zytcovicz T.H., Howard J.B. The mode of action of vitamin K: identification of carboxiglutamic acid as a component of prothrombin // J Biol Chem. 1974. — Vol. 249. — P. 6347−6350.
- Oldenburg J., Bevans C.G. et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles // Thromb Haemost. 2007. — Vol. 98(3). — P. 570−578.
- O’Reilly R., Rytand D. Resistance to warfarin due to unrecognized vitamin K supplementation//N Engl J Med. 1980. -Vol. 303.-P. 160−161.
- Orszulak T.A., Schaff H.V., Pluth J.R., et al. The risk of stroke in the early postoperative period following mitral valve replacement // Eur J Cardiothorac Surg 1995. Vol. 9. — P. 615−619.
- Palareti J., Legnani C., Guazzaloca G., et al. Risk factors for highly unstable response to oral anticoagulation: a case-control study // Br J Haematol. -2005. -Vol. 129.-P. 72−78.
- Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation // Stroke. 1988.-Vol. 19.-P. 15−18.
- Petersen P., Madsen E.B., Brun B., et al. Silent cerebral infarction in chronic atrial fibrillation //Stroke. 1987. -Vol. 18.-P. 1098−1100.
- Peverill R.E., Harper R.W., Grlman J., et al. Determinants of increased regional left atrial coagulation activity in patients with mitral stenosis // Circulation. 1996.-Vol. 94.-P. 331−339.
- Peyavandi F., Spreafico M., Siboni S.M., et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy // Clin Pharmacol Ther. 2004. — Vol. 75. — P. 198−203.
- Piccini J.P., Lopes R.D., Mahaffey K.W. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation // Curr Opin Cardiol. 2010. — Vol. 25(4).-P. 312−320.
- Pirmohamed M. Warfarin: almost 60 years old and still causing problems // Br J Clin Pharmacol. 2006. — Vol. 62. — P. 509−511.
- Pop G.A., Meeder H.J., Roelandt J.R. Transthoracic echo/Doppler in the identification of patients with chronic nonvalvular atrial fibrillation at risk for thromboembolic events//Eur Heart J. 1994.-Vol. 15.-P. 1545−1551.
- Prystowsky E.N. Management of atrial fibrillation: therapeutic options and clinical decisions // Am J Cardiol. 2000. — Vol. 85. — P. 3−11.
- Quaglini S., Cavallini A., Gerzeli S., et al. Economic benefit from clinical practice guideline compliance in stroke patient management //Health Policy. -2004.-Vol. 69(3).-P. 305−315.
- Redman A.R. Implications of cytochrome P450 2C9 polymorphism on metabolism and dosing // Pharmacotherapy. 2001. — Vol. 21. — P. 235−242.
- Reider M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose // N Engl J Med. 2005. — Vol. 352.-P. 2285−2293.
- Rettie A.E., Wienkers L.C., Gonzales F.J., et. al Impaired (s)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9 // Pharmacogenetics. 1994. — Vol. 4.-P. 39−42.
- Rice D.P., Miller L.S. Health economics and cost implications of anxiety and other mental disorders in the United States // Br J Psychiatry Suppl. 1998. -Vol. 34.-P. 4−9.
- Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials // Arch Intern Med. 1994. — Vol. 154(13). — P. 1449−1457.
- Rowan S., Bailey D., Bublitz C., et al. Trends in anticoagulation for atrial fibrillation in U.S. An analysis of the National Ambulatory Medical Care Survey Database // J Am Coll Cardiol. 2007. — Vol. 49. — P. 1561−1565.
- Salzberg S.P., Plass A., Emmert M.Y., et al. Left atrial appendage clip occlusion: early clinical results // J Thorac Cardiovasc Surg. 2010. — Vol. 139. — P. 1269−1274.
- Schwartz U.I., Ritche M.D., Bradford Y. et al. Genetic determinations of response to warfarin during initial anticoagulation // N Engl J Med. 2008. -Vol. 358.-P. 999−1008.
- Scone E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen // Blood. 2005. — Vol. 106.-P. 2329−2333.
- Scordo M.G., Pengo V., Spina E., et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms maintenance dose and metabolic clearance // Clin Pharmacol Ther. 2002. — Vol. 72. — P. 702−710.
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. EAFT Study Group // Lancet. 1993. — Vol. 342.-P. 1255−1262.
- Segel J.E. Cost-of-Illness Studies a Primer // Available from: http://www.rti.org/page.cfm/HealthEconomics.
- Serradel J.S., Bjornson D.C., Hartzema A.G. Drug utilization study methodologies: national and international perspectives // Drug Intell Clin Pharm. -1987.-Vol. 21.-P. 994−1001.
- Singer D., Albers G., Dalen J., et al. Antithrombotic Therapy in Atrial Fibrillation. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. 2008. — Vol. 133 — P. 546−529.
- Staffurth J.S., Gibberd M.C., Fui S.N. Arterial embolism in thyrotoxicosis with atrial fibrillation // BMJ. 1977. — Vol. 2. — P. 688−690.
- Stehle S., Kirchheiner J., Lazar A., et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization // Clin Pharmacokinet. 2008. — Vol. 47(9) .-P. 565−594.
- Stewart S., Hart C.L., Hole D.J., et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year of follow-up of the Renfrwe/Paisley study // Am J Med. 2002. — Vol. 113. — P. 359−364.
- Stewart S., Hart C.L., Hole D.J., et al. Population prevalence, incidence and predictors of atrial fibrillation in the Renfrew/Paisley study // Heart. 2001. -Vol. 86.-P. 516−521.
- Storm B.L. Study designs available for pharmacoepidemiology studies. In: Strom B.L., editor. Pharmacoepidemiology. 2nd ed. New York: John Wiley & Sons, Inc.- 1994. p. 15−29.
- Stroke in AF working group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review // Neurology. 2007. — Vol. 69:546−54.
- Stroke Prevention in Atrial Fibrillatio Study: final results // Circulation. -1991.-Vol. 84.-P. 527−539.
- Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: Echocardiographic features of patients at risk // Ann Intern Med. 1992. — Vol. 116. — P. 6−12.
- Strom B.L. When should one perform pharmacoepidemiology studies? In: Strom B.L., editor. Pharmacoepidemiology. 2nd ed. New York: John Wiley & Sons, Inc.- 1994. p. 57−69.
- Strom B.L. What is pharmacoepidemiology? In: Strom B.L., editor. Pharmacoepidemiology. 2nd ed. New York: John Wiley & Sons, Inc. 1994- p.3−15.
- Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorohism // Pharmacogenetics. 1996. — Vol. 6. — P. 341−349.
- Sunderberg M.I., Daly A.K., Nebert D.W. Human cytochrome P450 (CYP) allele nomenclature committee home page. Available from: http://www.imm.ki.se/CYPalleles. Accessed Feb 2006.
- Suttie J.W., Muhah-Schendel L.L., Shah D.V., et al. Vitamin K deficiency from dietary vitamin K restriction in humans // Am J Clin Nutr. 1988. — Vol. 47.-P. 475−480.
- Tabrizi A., Zehnabeur B., Borecki I., et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin // J Am Coll Surg. 2002. — Vol. 194. — P. 267−273.
- Taube J., Halsell D., Baglin T. Influence of cytochrome P-450 polymorphisms on warfarine sensitivity and risk of over-anticoagulation in patients on long-tern treatment // Blood. 2000. — Vol. 96. — P. 1816−1819.
- The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators //N Engl J Med. 1990. — Vol. 323. — P. 1505−1511.
- Viles-Gonzalez J.F., Fuster V., Halperin J.L. New anticoagulants for prevention of stroke in patients with atrial fibrillation // J Cardiovasc Electrophysiol. -2011. Vol. 22(8). — P. 948−955.
- Voora D., Eby C., Linder M.W., et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype // Thromb Haemost. 2005. — Vol. 93. — P. 700−705.
- Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting // Blood. 2009. — Vol. 113. — P. 784−792.
- Waif P.A., Dawber T.R., Thomas H.E., et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study // Neurology. 1978. — Vol. 28. — P. 973−977.
- Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study // Lancet. 1994. — Vol. 343.-P. 687−691.
- Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virhov’s triad revisited // Lancet. 2009. — Vol. 373. — P. 155−166.
- Wells P. S., Holbrook A.M., Crowther N.R., et al. The interaction of warfarin with drugs and food: a critical review of the literature // Ann Intern Med. -1994.-Vol. 121.-P. 676−683.
- WHO Drug Utilization Research Group (DURG). Validation of observed differences in the utilization of antihypertensive and anti-diabetic drugs in Northern Ireland, Norway and Sweden // Eur J Clin Pharmacol. 1985. — Vol. 29. -P. 1−8.
- Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study // Stroke. 1991. — Vol. 22. — P. 983 988.
- Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study // Arch Intern Med. 1987. — Vol. 147. — P. 1561−1564.
- Wolf P.A., D’Agostino R.B., Belanger A.J., et al. Probability of stroke: a risk profile from the Framingham study // Stroke. 1991. — Vol. 22. — P. 312−318.
- Wolf P.A., Dawber T.R., Thomas H.E., Kannel W.B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study // Neurology. 1978. — Vol. 28. — P. 973−977.
- World Health Organization Expert Committee. The selection of essential drugs. Geneva: World Health Organization, 1977.
- Wyse D., Waldo A., DiMarco J., et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate and rhythm control in patients with atrial fibrillation // N Engl J Med. 2002. -Vol. 347.-P. 1825−1833.
- Wysowslci D., Nourjan P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action // Arch Intern Med.-2007.-Vol. 167.-P. 1414−1419.
- Yamamoto K., Ikeda U., Seino Y., et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis // J Am Cardiol. 1995. — Vol. 25.-P. 107−112.
- Yin T., Miyata T. Warfarin dose and the pharmacogenetics of CYP2C9 and VKORC1 rationale and perspectives // Thrombosis Research. — 2007. — Vol. 120.-P. 1−10.
- Zimetbaum P.J., Thosani A., Yu H.T., et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? // Am J Med. 2010. -Vol. 123.-P. 446−453.